Adicet Bio Reports Q4 2025 Financial Results and Highlights Recent Progress in Autoimmune and Cancer Therapies.
ByAinvest
Thursday, Mar 12, 2026 4:05 pm ET1min read
ACET--
Adicet Bio reported solid Q4 and FY25 financial results, with strong enrollment progress in its prula-cel Phase 1 autoimmune study. Enrollment continues to advance ahead of expectations, and the company plans to submit a regulatory filing for ADI-212 in Q3 2026, with enrollment expected to begin in Q4 2026. The next clinical update for prula-cel is expected in H1 2026, with plans to initiate a pivotal study in LN or LN and SLE patients in H2 2026.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet